Diseases, Conditions, Syndromes

Researchers identify new therapeutic target for pulmonary fibrosis

Researchers in Japan have identified a genetic mutation that causes a severe lung disease called idiopathic pulmonary fibrosis (IPF) by killing the cells lining the lung's airways. The study, which will be published October ...

Diseases, Conditions, Syndromes

Damaging immune response may be cause of COPD infections

Researchers at the University of Dundee have made an important discovery about why patients with chronic obstructive pulmonary disease (COPD) suffer frequent chest infections, potentially paving the way for new treatments.

Inflammatory disorders

Early childhood bronchiolitis increases asthma risk in adulthood

Persons who have had bronchiolitis in early childhood have an increased risk of asthma at the age of 28-31 and a weaker health-related quality of life than their peers. In lung function tests, they also demonstrate changes ...

Medications

Opsumit approved for pulmonary arterial hypertension

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Immunology

T-cell responses in respiratory diseases

Respiratory illnesses are on the rise in an increasingly polluted world. Particularly, viral respiratory infections tend to aggravate previously existing respiratory illnesses, or cause life-long negative after-effects in ...

Diseases, Conditions, Syndromes

Anoro ellipta approved for COPD

(HealthDay)—A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.

page 6 from 12